Canadian consensus guidelines for the optimal use of maraviroc in the treatment of HIV-infected adults

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 21, Issue 4, 2010, Pages 159-172

  Rachlis, Anita ^a   Harris, Marianne ^b   Lalonde, Richard ^c   Shafran, Stephen D ^d   Tremblay, Cécile ^e   Wainberg, Mark A ^f   Walmsley, Sharon ^g  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^f MCGILL UNIVERSITY   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

CCR5 receptor antagonist; Entry inhibitors; HIV; Maraviroc; Recommendations; Resistance; Treatment; Tropism

Indexed keywords

APLAVIROC; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CLARITHROMYCIN; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; ENFUVIRTIDE; ETHINYLESTRADIOL; ETRAVIRINE; ITRACONAZOLE; KETOCONAZOLE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LEVONORGESTREL; LOPINAVIR PLUS RITONAVIR; MARAVIROC; MIDAZOLAM; NEFAZODONE; RALTEGRAVIR; RIFAMPICIN; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RITONAVIR PLUS TIPRANAVIR; SAQUINAVIR; TELITHROMYCIN; TENOFOVIR; TIPRANAVIR; UNINDEXED DRUG; ZIDOVUDINE;

ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; CANADA; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED CANCER; DRUG INDUCED HEADACHE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ESOPHAGUS CANDIDIASIS; FATIGUE; HEALTH CARE PERSONNEL; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HERPES SIMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MEDICAL DECISION MAKING; MONOTHERAPY; NAUSEA; NEUROTOXICITY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PHYSICIAN; PNEUMONIA; PRACTICE GUIDELINE; QT INTERVAL; REVIEW; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VASODILATATION; VIRAL TROPISM; VIRUS LOAD; VIRUS REPLICATION;

EID: 79953239648     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2010/303474     Document Type: Review

References (96)

1. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services, 2009:1-168. 〈www.aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf〉 (Accessed on March 29, 2010).
2. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society - USA panel. JAMA 2008;300:555-70.
3. Moore JP, Doms RW. The entry of entry inhibitors: A fusion of science and medicine. Proc Natl Acad Sci USA 2003;100:10598-602. (Pubitemid 37140074)
4. Shaheen F, Collman RG. Co-receptor antagonists as HIV-1 entry inhibitors. Curr Opin Infect Dis 2004;17:7-16. (Pubitemid 39089967)
5. Westby M, van der Ryst E. CCR5 antagonists: Host-targeted antivirals for the treatment of HIV infection. Antivir Chem Chemother 2005;16:339-54. (Pubitemid 41746045)
6. Moyle GJ, Wildfire A, Mandalia S, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005;191:866-72. (Pubitemid 40349800)
7. Kuhmann SE, Moore JP. The HIV-1 phenotypic variants - deadly and deadlier. J Viral Entry 2005;1:4-16.
8. Moore JP, Kitchen SG, Pugach P, et al. The CCR5 and CXCR4 co-receptors - central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retrovir 2004;20:111-26. (Pubitemid 38147183)
9. Poveda E, Briz V, Quinones-Mateu M, et al. HIV tropism: Diagnostic tools and implications for disease progression and treatment with entry inhibitors. AIDS 2006;20:1359-67. (Pubitemid 43948242)
10. Pickford C. The science of CCR5 inhibition. The Society for General Microbiology - 160th Meeting. Manchester, March 26 to 29, 2007. (Abst)
11. Brumme ZL, Goodrich J, Mayer HB, et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005;192:466-74. (Pubitemid 41023125)
12. Demarest J, Bonny T, Vavro C, et al. HIV-1 co-receptor tropism in treatment naive and experienced patients. The 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, October 30 to November 2, 2004. (Abst)
13. Coakley E, Benhamida J, Chappey C, et al. An evaluation of tropism profiles and other characteristics among 3988 individuals screened for the A4001026, A4001027 (MOTIVATE 1) and A4001028 (MOTIVATE 2) Phase 2b/3 studies of maraviroc. The 2nd International Workshop on Targeting HIV Entry. Boston, October 20 to 21, 2006. (Abst)
14. Wilkin TJ, Su Z, Kuritzkes DR, et al. HIV type 1 chemokine co-receptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 2007;44:591-5. (Pubitemid 46233265)
15. Agrawal L, Lu X, Qingwen J, et al. Role for CCR5Δ32 protein in resistance to R5, R5X4, and X4 human immunodeficiency virus type 1 in primary CD4+ cells. J Virol 2004;78:2277-87. (Pubitemid 38228921)
16. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996;382:722-5.
17. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 co-receptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-77. (Pubitemid 26272077)
18. McNicholl JM, Smith DK, Qari SH, et al. Host genes and HIV: The role of the chemokine receptor gene CCR5 and its allele (Δ32 CCR5). Emerg Infect Dis 1997;3:261-71. (Pubitemid 127431686)
19. Wu L, Paxton WA, Kassam N, et al. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med 1997;185:1681-91. (Pubitemid 27203264)
20. Glass WG, McDermott DH, Lim JK, et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 2006;203:35-40. (Pubitemid 43139642)
21. Eugen-Olsen J, Iversen AKN, Garret P, et al. Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS 1997;11:305-10. (Pubitemid 27086969)
22. Westby M, Smith-Burchnell C, Mori J, et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007;81:2359-71.
23. Hitchcock C. Discovery & exploratory development of maraviroc (UK-427,857) a CCR5 antagonist for the treatment of HIV/AIDS. The 2005 International Meeting of the Institute of Human Virology. Baltimore, August 29 to September 2, 2005. (Abst)
24. Lewis M. Bioinformatic support for the development of the CCR5 antagonist maraviroc (UK-427,857). InfoTech for Pharma & Biotech. London, March 12 to 15, 2007. (Abst)
25. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005;49:4721-32.
26. Ayoub A, van der Ryst, Turner K, et al. A review of the markers of immune function during the maraviroc Phase 1 and 2a studies. The 14th Conference on Retroviruses and Opportunistic Infections (CROI). Los Angeles, February 25 to 28, 2007. (Abst)
27. Celsentri Package Insert. Pfizer Inc, 2007.
28. Saag M, Goodrich J, Fatkenheuer G, et al. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis 2009;199:1638-47.
29. Swenson L, Dong W, Mo T, et al. Quantification of HIV tropism by "deep" sequencing shows a broad distribution of prevalence of X4 variants in clinical samples that is associated with virological outcome. The 16th Conference on Retroviruses and Opportunistic Infections (CROI). Montreal, February 8 to 11, 2009. (Abst)
30. Van der Ryst E, Westby M. Changes in HIV-1 co-receptor tropism for patients participating in the maraviroc MOTIVATE 1 and 2 clinical trials. The 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, September 17 to 20, 2007. (Abst)
31. Asmuth D, Goodrich J, Cooper D, et al. CD4 cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2. The XVII International AIDS Conference. Mexico City, August 3 to 8, 2008. (Abst)
32. Heera J, Saag M, Ive P, et al. Virological correlates associated with treatment failure at week 48 in the Phase 3 study of maraviroc in treatment-naive patients. The 15th Conference on Retroviruses and Opportunistic Infections. Boston, February 3 to 5, 2008. (Abst)
33. Valdez H, Lewis M, Delogne C, et al. Weighted OBT susceptibility score (wOBTSS) is a stronger predictor of virologic response at 48 weeks than baseline tropism result in MOTIVATE 1 and 2. The 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, October 25 to 28, 2008. (Abst)
34. Clax P, Rajicic N, Westby M, et al. Association between HIV-1 co-receptor tropism results and clinical and laboratory factors in 3,862 patients screened for phase 3 clinical studies of maraviroc. The 3rd International Workshop on Targeting HIV Entry. Washington, December 7 to 8, 2007. (Abst)
35. Fatkenheuer G, Nelson M, Lazzarin A, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. New Engl J Med 2008;359:1442-55.
36. Lazzarin A, Battegay M, Cooper DA, et al. CD4+ cell increases at 48 weeks in the maraviroc treatment-naïve MERIT trial. The 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, October 25 to 28, 2008. (Abst)
37. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. New Engl J Med 2008;359:1429-41.
38. Hardy WD, Gulick R, Mayer H, et al. Efficacy and safety of maraviroc in treatment-experienced patients infected with R5 HIV-1: 96-week combined analysis of the MOTIVATE 1 and 2 studies. The 9th International Congress on Drug Therapy in HIV Infection. Glasgow, November 9 to 13, 2008. (Abst)
39. Nelson M, Fisher M, Gonzalez-Garcia J, et al. Impact of baseline antiretroviral resistance status on efficacy outcomes among patients receiving maraviroc plus an optimized background therapy (OBT) versus placebo plus OBT in the MOTIVATE 1 and 2 trials. The XVII International AIDS Conference. Mexico City, August 3 to 8, 2008. (Abst)
40. 3. The 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, October 25 to 28, 2008. (Abst)
41. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348:2186-95. (Pubitemid 36618129)
42. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175-85. (Pubitemid 36618128)
43. Clotet B, Bellos N, Molina J-M, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials. Lancet 2007;369:1169-78. (Pubitemid 46541620)
44. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug resistant patients with Tipranavir (RESIST) studies: An analysis of combined data from two randomised open-label trials. Lancet 2006;368:466-75. (Pubitemid 44142769)
45. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008;359:355-65.
46. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359:339-54.
47. Gulick RM, van der Ryst E, Lampiris H, et al. Efficacy and safety of once-daily (OD) compared with twice-daily (BID) maraviroc plus optimized background therapy (OBT) in treatment-experienced patients infected with CCR5-tropic HIV-1: 24-week combined analysis of the MOTIVATE 1 and 2 studies. The 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, July 22 to 25, 2007. (Abst)
48. McFayden L, Jacqmin P, Wade JR, et al. Maraviroc (MVC) exposure-efficacy relationship in treatment-experienced HIV-1- infected patients. The 11th European AIDS Conference/EACS. Madrid, October 24 to 27, 2007. (Abst)
49. Weatherley B, McFayden L, Chan PLS, et al. Population pharmacokinetic covariate analysis of maraviroc in phase 2b/3 studies in treatment experienced (TE) HIV-1 infected patients on optimized background therapy (OBT). The 9th International Workshop on Clinical Pharmacology of HIV Therapy. New Orleans, April 9, 2008. (Abst)
50. Fatkenheuer G, Pozniak AL, Johnson MA, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005;11:1170-2. (Pubitemid 43093663)
51. Van der Ryst E, Fatkenheuer G, Pozniak A, et al. Maraviroc (UK-427,857), a novel CCR5 antagonist, demonstrates antiviral activity during 10-day monotherapy studies. The 1st International Workshop on Targeting HIV Entry. Baltimore, December 2 to 3, 2005. (Abst)
52. Saag M, Ive P, Heera J, et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine/ lamivudine), for the treatment of antiretroviral-naïve patients infected with R5 HIV-1: Week 48 results of the MERIT study. The 4th International AIDS Conference. Sydney, July 22 to 25, 2007. (Abst)
53. Saag M, Heera J, Goodrich J, et al. Reanalysis of the MERIT study with the Enhanced Trofile assay (MERIT-ES). The 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, October 25 to 28, 2008. (Abst)
54. McFayden L, Jacqmin P, Wade JR, et al. Maraviroc exposure-efficacy (<50 copies/mL) analysis in HIV-1-infected treatment-naïve patients - ITT population (MERIT study). The XVII International AIDS Conference (IAC). Mexico City, August 3 to 8, 2008. (Abst)
55. McGovern R, Dong W, Zhong X, et al. Population-based sequencing of the V3-loop is comparable to the enhanced sensitivity Trofile assay in predicting virologic response to maraviroc of treatment-naïve patients in the MERIT trial. The 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, February 16 to 19, 2010. (Abst)
56. Lewis M, Mori J, Simpson P, et al. Changes in V3 loop sequence associated with failure of maraviroc treatment in patients enrolled in the MOTIVATE 1 and 2 trials. The 15th Conference on Retroviruses and Opportunistic Infections (CROI). Boston, February 3 to 6, 2008. (Abst)
57. Mosley M, Smith-Burchnell C, Mori J, et al. Resistance to the CCR5 antagonist maraviroc is characterised by dose response curves that display a reduction in maximal inhibition (plateau). The 13th Conference on Retroviruses and Opportunistic Infections (CROI). Denver, February 5 to 9, 2006. (Abst)
58. Lewis M, Westby M, Smith-Buchnell C, et al. A genotypic analysis of HIV-1 sequences from emerging resistant virus after in vitro serial passage with CCR5 antagonist maraviroc (UK-427,857). The 3rd European HIV Drug Resistance Workshop. Athens, March 30 to April 1, 2005. (Abst)
59. Jubb B, Lewis M, Simpson P, et al. CCR5-tropic resistance to maraviroc is uncommon even among patients on functional maraviroc monotherapy or with ongoing low-level replication. The 16th Conference on Retroviruses and Opportunistic Infections (CROI). Montreal, February 8 to 11, 2009. (Abst)
60. Lewis M, van der Ryst E, Youle M, et al. Phylogenetic analysis and co-receptor tropism of HIV-1 envelope sequences from two patients with emergence of CXCR4 using virus following treatment with the CCR5 antagonist UK-427,857. The 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, October 30 to November 2, 2004. (Abst)
61. Westby M, Lewis M, Whitcomb J, et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006;80:4909-20.
62. Archer J, Braverman M, Taillon B, et al. Ultra-deep sequencing for detecting minority virus: Implications for ART. The 16th Conference on Retroviruses and Opportunistic Infections (CROI). Montreal, February 8 to 11, 2009. (Abst)
63. Lewis M, Simpson P, Fransen S, et al. CXCR4-using virus detected in patients receiving maraviroc in the phase 3 studies MOTIVATE 1 and 2 originates from a pre-existing minority of CXCR4-using virus. The XVI International HIV Drug Resistance Workshop. Barbados, June 12 to 16, 2007. (Abst)
64. Waters L, Scourfield A, Marcano M, et al. The evolution of co-receptor tropism in patients interrupting suppressive HAART. The 16th Conference on Retroviruses and Opportunistic Infections (CROI). Montreal, February 8 to 11, 2009. (Abst)
65. Deeks SG, Hoh R, Neilands TB, et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis 2005;192:1537-44. (Pubitemid 41504689)
66. Deeks SG, Lu J, Hoh R, et al. Interruption of enfuvirtide in HIV-1-infected adults with incomplete viral suppression on an enfuvirtide-based regimen. J Infect Dis 2007;195:387-91. (Pubitemid 46146116)
67. Trinh L, Han D, Huang W, et al. Validation of an enhanced sensitivity Trofile™ HIV-1 co-receptor tropism assay. The 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, October 25 to 28, 2008. (Abst)
68. Trofile Co-Receptor Tropism Assay. What is Trofile. 〈www. trofileassay.com/what-is-trofile.html〉 (Accessed on March 29, 2010).
69. Harrigan R. Predicting response to CCR5 antagonists. The 16th Conference on Retroviruses and Opportunistic Infections (CROI). Montreal, February 8 to 11, 2009. (Abst)
70. Ayoub A, Goodrich J, van der Ryst, et al. Adverse event profile of maraviroc in treatment-experienced patients infected with R5 HIV-1. The 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, October 25 to 28, 2008. (Abst)
71. Nichols WG, Steel HM, Bonny T, et al. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob Agents Chemother 2008;52:858-65. (Pubitemid 351358363)
72. Hoepelman IM, Ayoub A, Heera J, et al. The incidence of severe liver enzyme abnormalities and hepatic adverse events in the maraviroc clinical development programme. The 11th European AIDS Conference (EACS). Madrid, October 24 to 27, 2007. (Abst)
73. Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS Clinical Trials Group 5211. J Infect Dis 2007;196;304-12. (Pubitemid 47047471)
74. Maguire JJ, Kuc RE, Katugampola SD, et al. Novel function of the inflammatory chemokine MIP-1$, a ligand for the HIV co-receptor CCR5, as a vasoconstrictor of human blood vessels: Antagonism by maraviroc. The Annual Scientific Meeting of the British Hypertension Society. Cambridge, September 24 to 26, 2007. (Abst)
75. McHale M, Abel S, Russell D, et al. Overview of phase 1 and 2a safety and efficacy data of maraviroc (UK-427,857). The 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, July 24 to 27, 2005. (Abst)
76. Russell D, Weissgerber G, Wooldridge C, et al. Investigation into the haemodynamic effects of oral maraviroc (UK-427,587) in healthy volunteers. The 10th European AIDS Conference (EACS). Dublin, November 17 to 20, 2005. (Abst)
77. Davis J, Hackman F, Sudworth D, et al. A single dose study to investigate the effect of the CCR5 antagonist maraviroc (UK-427,587) on the QTc interval in healthy patients. The 6th International Workshop on Clinical Pharmacology of HIV Therapy. Quebec, April 26 to 29, 2005. (Abst)
78. DeJesus E, Walmsley S, Cohen C, et al. Fasted lipid changes after administration of maraviroc or efavirenz in combination with zidovudine and lamivudine (Combivir) for 48 weeks to treatment-naïve HIV-infected patients. The 15th Conference on Retroviruses and Opportunistic Infections (CROI). Boston, February 3 to 6, 2008. (Abst)
79. Ayoub A, Goodrich J, Tressler R, et al. Incidence of infections in treatment-experienced patients infected with R5 HIV-1 in the MOTIVATE studies of maraviroc in combination with optimized background therapy. The 9th International Congress on Drug Therapy in HIV Infection. Glasgow, November 9 to 13, 2008. (Abst)
80. American Academy of Pediatrics, Pediatric Care Online. FDA Pregnancy Categories. 〈http://www.pediatriccareonline.org/pco/ub/view/Pediatric-Drug- Lookup/153860/0/FDA-Pregnancy-Categories〉 (Accessed on March 29, 2010).
81. Abel S, Ridgway C, Hamlin J, et al. An open, parallel group study to compare the pharmacokinetics, safety and toleration of a single oral dose of maraviroc in patients with mild and moderate hepatic impairment with patients with normal hepatic function. The 8th International Workshop on Clinical Pharmacology of HIV Therapy. Budapest, April 16 to 18, 2007. (Abst)
82. Fatkenheuer G, Pozniak A, Johnson M, et al. Evaluation of dosing frequency and food effect on viral load reduction during short-term monotherapy with UK-427,857, a novel CCR5 antagonist. The 15th International AIDS Conference. Bangkok, July 11 to 16, 2004. (Abst)
83. Dumond JB, Patterson KB, Pecha A, et al. Maraviroc pharmacokinetics in blood plasma, genital tract fluid and tissue in healthy female volunteers. The 15th Conference on Retroviruses and Opportunistic Infections (CROI). Boston, February 3 to 6, 2008. (Abst)
84. Abel S, Russell D, Ridgway C, et al. Overview of the drug-drug interaction data for maraviroc (MVC, UK-427,857). The 6th International Workshop on Clinical Pharmacology of HIV Therapy. Quebec, April 28 to 30, 2005. (Abst)
85. Jenkins T, Abel S, Russell D, et al. The effect of P450 inducers on the pharmacokinetics of CCR5 antagonist, UK-427,857, in healthy volunteers. The 5th International Workshop on Clinical Pharmacology of HIV Therapy. Rome, April 1 to 3, 2004. (Abst)
86. Abel S, Russell D, Ridgway C, et al. Effect of CYP3A4 inhibitors on the pharmacokinetics of CCR5 antagonist UK-427,857 in healthy volunteers. The 5th International Workshop on Clinical Pharmacology of HIV Therapy. Rome, April 1 to 3, 2004. (Abst)
87. Abel S, Russell D, Ridgway C, et al. Effect of CCR5 antagonist UK-427,857 on the pharmacokinetics of CYP3A4 substrates in healthy volunteers. The 5th International Workshop on Clinical Pharmacology of HIV Therapy. Rome, April 1 to 3, 2004. (Abst)
88. Abel S, Whitlock L, Ridgway C, et al. Effect of UK-427,857 on the pharmacokinetics of oral contraceptive steroids, and the pharmacokinetics of UK-427,857 in healthy young women. The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, September 14 to 17, 2003. (Abst)
89. Abel S, Ridgway C, Hamlin J, et al. An open, randomized 2-way crossover study to investigate the effect of darunavir/ritonavir on the pharmacokinetics of maraviroc in healthy patients. The 8th International Workshop on Clinical Pharmacology of HIV Therapy. Budapest, April 16 to 18, 2007. (Abst)
90. Abel S, Taylor-Worth R, Ridgway C, et al. Effect of tipranavir/ritonavir on the pharmacokinetics of maraviroc (MVC, UK-427,857). The 7th International Workshop on Clinical Pharmacology of HIV Therapy. Lisbon, April 20 to 22, 2006. (Abst)
91. Andrews E, Glue P, Fang J, et al. A pharmacokinetic study to evaluate an interaction between maraviroc and raltegravir in healthy adults. The 48th Annual ICAAC/IDSA 46th Annual Meeting. Washington, October 25 to 28, 2008. (Abst)
92. Davis J, Scholler-Gyure M, Kakuda TN, et al. An open, randomized, two-period, crossover study in two cohorts to investigate the effect of steady state TMC125 (etravirine) and the combination of TMC125/darunavir/ritonavir on the steady-state pharmacokinetics of oral maraviroc in healthy patients. The 11th European AIDS Conference (EACS). Madrid, October 24 to 27, 2007. (Abst)
93. Muirhead G, Russell D, Abel S, et al. An investigation of the effects of tenofovir on the pharmacokinetics of the novel CCR5 inhibitor UK-427,857. Seventh International Congress on Drug Therapy in HIV Infection. Glasgow, November 14 to 17, 2004. (Abst)
94. Muirhead G, Pozniak A, Gazzard B, et al. A novel probe drug interaction study to investigate the effect of selected ARV combinations on the pharmacokinetics of a single oral dose of maraviroc (UK-427,587) in HIV +ve patients. The 12th Conference on Retroviruses and Opportunistic Infections. Boston, February 22 to 25, 2005. (Abst)
95. Ramanathan S, West S, Abel S, et al. Pharmacokinetics of coadministered ritonavir-boosted elvitegravir plus maraviroc. The 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, September 17 to 20, 2007. (Abst)
96. Russell D, Ridgway C, Mills C, et al. A study to investigate the combined co-administration of P450 CYP3A4 inhibitors and inducers on the pharmacokinetics of the novel CCR5 inhibitor UK-427,587. The 7th International Congress on Drug Therapy in HIV Infection. Glasgow, November 14 to 18, 2004. (Abst)